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Abstract
Background: Limited data are available on the characteristics, clinical management, and outcomes of patients with atrial
fibrillation at risk of stroke, from a worldwide perspective. The aim of this study was to describe the baseline characteristics
and initial therapeutic management of patients with non-valvular atrial fibrillation across the spectrum of sites at which
these patients are treated.
Methods and Findings: The Global Anticoagulant Registry in the FIELD (GARFIELD) is an observational study of patients
newly diagnosed with non-valvular atrial fibrillation. Enrollment into Cohort 1 (of 5) took place between December 2009
and October 2011 at 540 sites in 19 countries in Europe, Asia-Pacific, Central/South America, and Canada. Investigator sites
are representative of the distribution of atrial fibrillation care settings in each country. Cohort 1 comprised 10,614 adults
($18 years) diagnosed with non-valvular atrial fibrillation within the previous 6 weeks, with $1 investigator-defined stroke
risk factor (not limited to those in existing risk-stratification schemes), and regardless of therapy. Data collected at baseline
included demographics, medical history, care setting, nature of atrial fibrillation, and treatments initiated at diagnosis. The
mean (SD) age of the population was 70.2 (11.2) years; 43.2% were women. Mean6SD CHADS2 score was 1.961.2, and
57.2% had a score $2. Mean CHA2DS2-VASc score was 3.261.6, and 8,957 (84.4%) had a score $2. Overall, 38.0% of patients
with a CHADS2 score $2 did not receive anticoagulant therapy, whereas 42.5% of those at low risk (score 0) received
anticoagulant therapy.
Conclusions: These contemporary observational worldwide data on non-valvular atrial fibrillation, collected at the end of
the vitamin K antagonist-only era, indicate that these drugs are frequently not being used according to stroke risk scores
and guidelines, with overuse in patients at low risk and underuse in those at high risk of stroke.
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Introduction
Atrial fibrillation (AF) is the most common heart rhythm
disorder, with approximately one-quarter of individuals over 40
years of age developing this arrhythmia [1]. The risk of stroke –
including ischemic stroke, hemorrhagic stroke and cerebral bleeds
– increases fivefold among patients with AF [2]. AF is also
associated with a twofold excess risk of cardiovascular death and
stroke within 1 year of observation [3].
Vitamin K antagonists (VKAs) have served as the cornerstone
of stroke prevention in AF for several decades. Comprehensive
evidence-based management guidelines [4,5,6,7] advocating the
use of risk scores to identify patients most (or least) at risk of
thrombotic or bleeding events are widely available. VKAs have a
number of drawbacks, however, including a narrow therapeutic
window, multiple food and drug interactions [8], and substantial
inter-patient variability due to genetic or other factors, making
their long-term use in clinical practice a challenge [9]. Physicians
remain reluctant to prescribe anticoagulant prophylaxis in a large
proportion of the population at risk for stroke, in part due to the
limitations of VKAs, misperception of thrombotic risk [10], and
concern about bleeding complications, especially among the
elderly [11].
International observational studies have provided insights into
the characteristics, risk profiles, management, and clinical
outcomes of patients with various cardiovascular diseases
[12,13]. Less is known about individuals newly diagnosed with
AF and perceived to be at risk of stroke by their physicians, and
few data are available that reflect the broad range of healthcare
settings for AF from a worldwide perspective.
The Global Anticoagulant Registry in the FIELD (GARFIELD)
was initiated to describe everyday antithrombotic treatment
patterns in patients newly diagnosed with non-valvular AF and
one or more additional investigator-defined stroke risk factor
across the spectrum of care settings at which these patients are
treated, and to understand the burden of thromboembolic and
bleeding complications in this population. This article presents the
baseline characteristics and initial management of the first of five
cohorts of over 10,000 patients enrolled in the GARFIELD
Registry.
Methods
Ethics Statement
Independent ethics committee and hospital-based institutional
review board approvals were obtained, as necessary, for the
registry protocol. (See Ethics List S1) The registry is being
conducted in accordance with the principles of the Declaration of
Helsinki, local regulatory requirements, and the International
Conference on Harmonisation–Good Pharmacoepidemiological
and Clinical Practice guidelines. All patients provided written
informed consent to participate.
Trial Design and Participants
The GARFIELD Registry is an ongoing, observational,
multicenter, worldwide study of adults ($18 years) with non-
valvular AF diagnosed according to standard local procedures
within the past 6 weeks (electrocardiogram confirmation was not
mandated) and $1 additional factor judged by the clinician to
increase the patient’s risk of stroke; such factors were not
prespecified in the protocol, nor were they limited to the factors
in risk-stratification schemes such as CHADS2 (cardiac failure,
hypertension, age, diabetes, stroke [doubled]) [14] or CHA2DS2-
VASc (cardiac failure, hypertension, age $75 [doubled], diabetes,
stroke [doubled]-vascular disease, age 65–74 and sex category
[female]) [15].
Enrollment will take place in five independent, sequential
cohorts [16]. Patient enrollment into Cohort 1 took place between
21 December 2009 and 26 October 2011. In parallel with
prospectively enrolled patients, a validation group (part retrospec-
tive and part prospective) was enrolled, comprising patients with
established AF (i.e., AF first diagnosed $6 months and #24
months before enrollment) and$1 additional risk factor for stroke,
regardless of therapy; in these patients, data were collected
retrospectively to the time of first AF diagnosis, and prospectively
up to 2 years after diagnosis. The rationale for the inclusion of the
retrospective cohort was to evaluate, by comparing retrospective
with prospective data, whether initiation of the GARFIELD
Registry influenced AF management patterns on a site level; if the
effect was zero or minimal, the data from both cohorts would to be
combined.
Patients for whom follow-up up to 2 years was unlikely and
those with a transient reversible cause of AF were excluded. Data
were collected using an electronic case report form (eCRF) [16].
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Investigator sites are representative of the distribution of AF
treating care settings in each country. Sufficient sites were
identified from the spectrum of care settings (office-based practice,
hospital departments [neurology, cardiology, geriatrics, internal
medicine, emergency], anticoagulant clinics, and general or family
practice) to ensure proportional representation in all countries,
and the lists and ratios were validated by national coordinators
[16]. Sites were selected randomly and recruited following a
qualification call. Before site initiation, investigators were required
to complete a training program that provided guidance on patient
screening, enrollment, and follow-up. Patients were enrolled
consecutively, as stipulated in the protocol.
Procedures
Data collected at baseline included patient and clinical
characteristics at diagnosis, medical history (including cardiovas-
cular and bleeding history), care setting at diagnosis, type of AF,
date and method of diagnosis, symptoms, antithrombotic treat-
ment at diagnosis (VKAs, factor Xa inhibitors, thrombin
inhibitors, and heparins), and reasons for not providing VKAs
(when applicable). Ethnicity was classified by the investigator, in
agreement with the patient, to investigate ethnic differences in the
prevalence of AF [17].
Heart failure, hypertension (blood pressure .140/90 mmHg or
treated hypertension), age $75 years, diabetes mellitus, and prior
stroke or transient ischemic attack were used to calculate,
retrospectively, stroke risk according to the CHADS2 risk index
[14]. Additionally, left ventricular ejection fraction ,40%, prior
thromboembolism, vascular disease (acute coronary syndrome,
peripheral artery disease), age 65–74 years, and female gender
were used to determine stroke risk using the CHA2DS2-VASc
score [15].
Registry data were captured in electronic CRFs (designed by
Dendrite Clinical Systems Ltd, Henley-on-Thames, UK, who are
also responsible for ongoing database programme management).
Data collection and entry are managed by Quintiles (Durham,
NC, USA), who oversee all operational aspects of the programme,
apart from in the UK where these aspects are undertaken by The
University of Birmingham Department of Primary Care Clinical
Sciences. Submitted data are examined by the coordinating center
(Thrombosis Research Institute, London) to ascertain their
completeness and accuracy, and data queries are sent to
participating sites. Data are extracted for each analysis and
analyzed by an independent statistician (PW). Confidentiality and
anonymity of all patients enrolled into this registry was maintained
at all times.
Statistical Analysis
Continuous variables are expressed as mean6standard devia-
tion (SD). Categorical variables are expressed as frequencies and
percentages. Differences between cohorts were tested for statistical
significance using the Chi-squared test for categorical variables
and the unpaired t-test for continuous variables. Statistical analysis
was performed using SASH software version 9.1.3 (SAS Institute
Inc., Cary, NC, USA).
Results
A total of 10,614 patients were enrolled into Cohort 1 at 540
sites in 19 countries in Asia-Pacific (n = 2,940, 27.7%; Australia,
Figure 1. Number of patients enrolled per country in Cohort 1 (n=10,614).
doi:10.1371/journal.pone.0063479.g001
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China, Korea, Japan), Canada (n = 237, 2.2%), Europe (n= 6,580,
62.0%; Austria, Denmark, Finland, France, Germany, Italy,
Netherlands, Norway, Poland, Spain, Sweden, UK), and Cen-
tral/South America (n = 857, 8.1%; Brazil, Mexico) (Figure 1).
More than half of the patients (n = 6,262, 59.0%) were enrolled by
cardiologists, 20.8% (n= 2,208) by internal medicine specialists,
17.7% (n= 1,880) by primary care/general practice physicians,
2.1% (n= 218) by neurologists, and 0.4% by geriatricians (n = 40)
(data for six patients unknown). Each site recruited 20 consecutive
patients on average. Baseline data were locked in 99.9% of the
patients.
Overall, 29.7% of patients had new or unclassified AF, 27.5%
had paroxysmal AF, 17.9% had persistent AF, and 24.9% had
permanent AF. White patients represented the largest percentage
of the population (62.2%), followed by Asians (7.6% Chinese and
17.0% other Asian ethnicities); the remaining patients were
White–Hispanic/Latino (8.2%), mixed/other (1.2%), Afro-Carib-
bean (0.3%), or of unknown race (3.5%).
Table 1. Patient baseline characteristics: Cohort 1 of the GARFIELD Registry.
Variable All patients (n =10,614)
Age, mean (SD), years 70.2611.2
Age group, n (%)
.65 years 7,374 (69.5)
$75 years 4,091 (38.5)
65–74 years 3,540 (33.4)
Women, n (%) 4,580 (43.2)
Body mass index,a mean (SD), kg/m2 27.565.3
Smoking status (current/previous)b, n (%) 3,504 (35.2)
Pulse,c mean (SD), bpm 86.6625.1
Medical history, n (%)
Acute coronary syndromes (myocardial infarction or unstable angina) 1,060 (10.0)
Congestive heart failured 2,229 (21.0)
Coronary artery diseased 2,035 (19.2)
Hypercholesterolemiad 4,159 (39.2)
Hypertensiond 8,249 (77.8)
Family history of cardiac diseasee,f 1,940 (18.3)
Diabetes mellitusf 2,330 (22.0)
Stroked 1,026 (9.7)
Stroke or transient ischaemic attackd 1,528 (14.4)
Left ventricular ejection fraction ,40%g 586 (9.5)
Chronic renal diseaseh
Mild renal dysfunction (GFR 60–89 mL/min) 1,502 (19.6)
Moderate renal dysfunction (GFR 30–59 mL/min) 871 (11.4)
Severe renal dysfunction or renal failure (GFR ,30 mL/min) 154 (2.0)
Peripheral artery diseased 743 (7.0)
Carotid occlusive diseased 368 (3.5)
Other thromboembolismd,i 150 (1.4)
Systemic embolismd 80 (0.8)
Pulmonary embolism or deep vein thrombosisd 304 (2.9)
Bleedingd 368 (3.5)
Heavy alcohol consumptionj 215 (2.2)
Cirrhosisd 55 (0.5)
Abbreviation: GFR, glomerular filtration rate.
aData not available for 1,611 patients.
bData not available for 671 patients.
cData not available for 1,372 patients.
dData not available for 6 patients.
eFirst-degree relative with premature cardiac history (age ,55 years [male], ,65 years [female]).
fData not available for 7 patients.
gData not available for 4,448 patients.
hData not available for 2,954 patients.
iFor example, central venous thrombosis, retinal occlusion.
jInvestigator defined; data not available for 1,048 patients.
doi:10.1371/journal.pone.0063479.t001
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Of the overall cohort of 10,614 patients, 5,089 (47.9%) were
enrolled retrospectively and 5,525 (52.1%) prospectively (see
Figure S1 for year of diagnosis). No statistical or clinical concerns
were apparent regarding any of the differences in baseline
characteristics of the retrospectively and prospectively enrolled
patients that would preclude combining the data from these two
groups (Table S1, Figure S2), hence combined results are reported.
Baseline characteristics are given in Table 1. The mean6SD
age was 70.2611.2 years and 69.5% of patients were .65 years;
43.2% were women. More than three-quarters (77.8%) of the
population had hypertension, 22.0% had diabetes mellitus, 21.0%
had congestive heart failure, and 9.7% of patients had a history of
stroke. Over one-third (35.2%) of patients were current or previous
smokers. The mean6SD CHADS2 score was 1.961.2, and 57.2%
(6,062/10,607) of patients had a score $2, indicating a moderate
to high risk of stroke and guideline qualification for oral
anticoagulant treatment. Mean6SD CHA2DS2-VASc score was
3.261.6, and 84.4% (8,957/10,607) had a score $2. The
distributions of risk scores for stroke are shown in Figure 2.
At diagnosis, 55.8% of patients overall were given a VKA for
stroke prevention: 45.2% (n= 4,797) received a VKA alone and
10.6% (n= 1,128) received both a VKA and an antiplatelet drug
(Figure 3). A minority of patients (4.5%, n= 475) received a novel
oral factor Xa inhibitor or direct thrombin inhibitor. Just over
one-quarter (25.3%, n= 2,681) of the patients received an
antiplatelet drug alone and 14.4% (n= 1,533) received none of
these antithrombotic drugs. Use of antithrombotic drugs at AF
diagnosis and contraindications to anticoagulant therapy are
detailed in Table 2. The most frequently given antiplatelet was
aspirin. Use of all antithrombotic drugs was higher in patients with
a CHADS2 score of 2–6 versus those with a score of 0 or 1.
Contraindications to anticoagulant therapy were reported in 827
(7.8%) of patients.
The use of anticoagulant therapy by CHADS2 risk score is
shown in Figure 3A. VKA use (alone or with an antiplatelet)
Figure 2. Distribution of CHADS2 and CHA2DS2-VASc scores (n=10,607) (scores not available for 7 patients).
doi:10.1371/journal.pone.0063479.g002
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increased as risk level increased, up to a maximum of 63% at a
CHADS2 score of 3 and 4, then decreased thereafter. Use of novel
factor Xa inhibitors and direct thrombin inhibitors was low across
all risk categories. Overall, 38.0% (2,302/6,062) of patients with a
CHADS2 score $2 did not receive anticoagulant therapy;
conversely, 42.5% (364/857) of those at low risk (score of 0)
received anticoagulant therapy. Similar patterns were observed
when risk was assessed according to the CHA2DS2-VASc score:
40.7% (3,645/8,957) of the patients with a score $2 did not
receive anticoagulant therapy, and 38.7% (118/305) of patients
with a score of 0 received anticoagulant therapy (Figure 3B). For
both risk scores, use of antiplatelet therapy showed an initial
decline with rising risk level.
The reasons for not providing VKA therapy to patients at
moderate to high risk of stroke are given in Table 3. Almost half of
the reasons for not providing VKA related to physician choice.
Discussion
This large, ongoing, international observational study of
patients newly diagnosed with non-valvular AF and one or more
additional risk factors for stroke provides a unique perspective of
AF management at the end of the VKA-only era, transitioning
into the period in which novel oral anticoagulants present an
alternative treatment for stroke prevention. The data illustrate the
high rate of comorbid conditions in this population, including
hypertension, hypercholesterolemia, diabetes mellitus, heart fail-
ure, and coronary artery disease. A sizable proportion of the
population had a history of stroke or transient ischemic attack.
Nearly 6/10 patients presented with a CHADS2 score $2 and
more than 8/10 with a CHA2DS2VASc score $2. These figures
correlate with an annual adjusted stroke rate ranging from 3.4%
for a CHADS2 score of 2 to 18.2% for a score of 6 [14], and from
2.2% for a CHA2DS2-VASc score of 2 to 15.2% for a score of 9
[15]. Despite this high level of thromboembolic risk, overall use of
anticoagulant therapy was relatively low. A total of 40.7% of the
patients with a CHA2DS2-VASc score $2 did not receive
guideline-recommended anticoagulant prophylaxis [5,6,7,18].
Conversely, 38.7% of the patients with a CHA2DS2-VASc score
of 0 received anticoagulant therapy; these individuals are regarded
as ‘‘truly’’ low-risk subjects, with a stroke/thromboembolism event
rate of 0.84 (95% confidence interval [CI], 0.65–1.08) per 100
person-years in patients with AF, compared with 3.49 (95% CI,
3.31–3.68) per 100 person-years for AF patients with a CHADS2
score of 0 or 1 [19]. Our present study, in which risk stratification
was done retrospectively through a review of data collected in the
eCRFs, indicates that the identification in ‘‘real-world’’ practice of
patients perceived to be at risk of stroke is often not based on
evidence-based risk schemes and guidelines [6]. There appears to
be overuse of anticoagulant therapy in patients at low risk of stroke
or systemic embolism, and underuse in those at moderate to high
risk. Physicians’ clinical judgment of stroke risk therefore appears
to incorporate factors beyond those included in CHADS2 and
CHA2DS2-VASc.
Table 2. Use of antithrombotic drugs at diagnosis and contraindications to anticoagulant therapy, overall and according to
CHADS2 scores of 0 or 1 and 2–6.
Drug All patients (n =10,614)
Patients with CHADS2
score of 0 or 1 (n =4,367)
Patients with CHADS2
score of 2–6 (n=6,240)
Antiplateleta,b, n (%)
Aspirin 2,713 (26.5) 1166 (28.4) 1547 (25.2)
Thienopyridine 713 (7.0) 229 (5.6) 484 (7.9)
Glycoprotein IIb/IIIa inhibitor 16 (0.2) 6 (0.1) 10 (0.2)
Prostaglandin analogue 18 (0.2) 6 (0.1) 12 (0.2)
Other antiplatelet 102 (1.0) 30 (0.7) 72 (1.2)
Anticoagulant drugsa,c, n (%)
Vitamin K antagonist 6,080 (58.2) 2218 (52.8) 3861 (61.9)
Heparin (unfractionated or low-molecular-weight) 410 (3.9) 151 (3.6) 259 (4.2)
Factor Xa inhibitor (oral or injectable) 312 (3.0) 102 (2.4) 210 (3.4)
Direct thrombin inhibitor (e.g., argatroban, dabigatran,
bivalirudin, desirudin)
128 (1.2) 43 (1.0) 85 (1.4)
Heparinoid (e.g., danaparoid, sulodexide, dermatan sulfate) 89 (0.9) 35 (0.8) 54 (0.9)
Other anticoagulant (e.g., defibrotide, ramatroban,
antithrombin III, protein C)
31 (0.3) 9 (0.2) 22 (0.4)
Contraindication to anticoagulant therapy, n (%)a
Excessive bleeding risk 289 (2.7) 88 (2.0) 201 (3.2)
Frequent falls or mechanical risk 238 (2.2) 38 (0.9) 200 (3.2)
Risk of drug interaction 39 (0.4) 13 (0.3) 26 (0.4)
Allergy 11 (0.1) 2 (,0.1) 9 (0.1)
Other contraindication 249 (2.3) 76 (1.7) 174 (2.8)
aCategories are not mutually exclusive.
bData not available for 360 patients.
cData not available for 171 patients.
doi:10.1371/journal.pone.0063479.t002
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Comparison of GARFIELD with Other Registries in Non-
valvular AF
One of the largest multinational studies in this field is the Euro
Heart Survey on Atrial Fibrillation, conducted between 2003 and
2004 in more than 5,000 ambulatory and hospitalized patients
[20]. The Euro Heart Survey provided a snapshot of the
management of AF across 35 European Society of Cardiology
member countries and revealed discordance between guidelines
and everyday clinical practice. Oral anticoagulation was pre-
scribed in 67% of patients considered eligible for VKA treatment
according to guidelines [4], but also in 49% of ineligible patients.
The Euro Heart Survey did indicate an increase in use of oral
anticoagulant therapy with increasing stroke risk [21], in contrast
to the results of a large nationwide retrospective US medical
claims database study involving over 171,000 patients with AF
Figure 3. Use of antithrombotic therapies, overall and according to (A) CHADS2 score and (B) CHA2DS2VASc score (n=10,607). AP
indicates antiplatelet; FXa/DTI, activated coagulation factor X inhibitor/direct thrombin inhibitor (irrespective of AP use); VKA, vitamin K antagonist.
doi:10.1371/journal.pone.0063479.g003
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(51,907 of whom had newly diagnosed AF), which indicated a low
use of warfarin across all risk categories (overall rate 42.6%; 49.5%
in patients newly diagnosed with AF) [22]. Both studies were
consistent, however, in reporting underuse of oral anticoagulation
in patients at elevated risk and overuse in those at low risk. Our
present data show no apparent improvement in adherence to
evidence-based guidelines [5,6,18] for AF in recent years.
Despite mandating the presence of one or more additional
stroke risk factors in an effort to exclude patients with lone AF, the
GARFIELD population fares as relatively low risk compared with
other observational cohorts, and is substantially lower risk than the
populations included in randomized trials of novel oral anticoag-
ulant drugs (Table 4) [23,24,25,26]. ‘‘Additional risk factors’’ were
investigator defined in order to identify patients that physicians
themselves perceived – during the course of their usual practice –
to be at risk of stroke. This approach contrasts with other studies
that mandated the presence of one or more specific risk factors,
such as prior stroke or transient ischemic attack, hypertension, and
heart failure, resulting in much higher-risk populations than
typically seen in everyday clinical practice. Further, other data sets
have been based on patients identified in emergency departments
or hospitalized for another condition, who may be at high risk of a
poor outcome [27]. In the nationwide US Outcomes Registry for
Better Treatment of Atrial Fibrillation (ORBIT-AF) [28], for
example, the mean6SD CHADS2 score was 2.361.3 [28], the
mean age was 76 years, and approximately 30% of patients had
diabetes and 30% heart failure. In contrast, in GARFIELD, the
mean CHADS2 score was 1.961.2, mean age was 70 years, and
only 22% patients had diabetes and 21% had heart failure. The
differences in these two study populations may be due the fact that
GARFIELD enrolled patients newly diagnosed with AF whereas
ORBIT-AF enrolled patients with prevalent or incident AF.
RealiseAF was a large, international, contemporary, cross-
sectional study conducted in 10,523 outpatients in 26 countries
between 2009 and 2010 [29], with the aim of investigating the
success of rhythm versus rate control, and the impact of control on
patients’ clinical symptoms and quality of life. The patients in this
registry were slightly younger than those in GARFIELD (67 vs. 70
years), and they had higher rates of heart failure (46% vs. 21%),
coronary artery disease (32% vs. 19%) and hypercholesterolemia
(46% vs. 39%); these differences in baseline characteristics likely
reflect differences in the treatment settings. In RealiseAF, for
example, all of the patients were enrolled by cardiologists or
internists (hospital- and office-based), whereas in GARFIELD the
aim was to reflect the spectrum of care settings in each country;
consequently 80% of the patients were enrolled by cardiologists or
internists, 18% were enrolled by primary care/general practice
physicians, and 2.1% were enrolled by neurologists. Furthermore,
62% of the RealiseAF population was diagnosed with AF .12
months previously, whereas patients in GARFIELD were newly
diagnosed, a finding supported by the higher rate of permanent
AF in RealiseAF (46% vs. 25%).
Several other large registries in AF have been launched recently,
including the international Global Registry on Long-Term Oral
Antithrombotic Treatment in Patients with Atrial Fibrillation
(GLORIA-AF), and the nationwide US Practice INNovation And
Clinical Excellence (PINNACLE-AF) registry – part of the
American College of Cardiology National Cardiovascular Data
Registry. Physician participation in PINNACLE-AF is voluntary,
and the study will report on outcomes in 121,000 patients with AF
[30]. Like GARFIELD, PINNACLE-AF will rigorously assess
current and evolving practice patterns; it will also help US
providers evaluate and improve adherence to guidelines and
performance measures through the provision of checklists of
guideline-recommended care and provision of quarterly reports.
These national US data will be complementary to GARFIELD,
which will be conducted in up to 35 countries throughout the
world.
Future Insights from the GARFIELD Registry
The second GARFIELD cohort was initiated in October 2011,
and an additional 11 countries (Argentina, Belgium, Chile, Czech
Republic, Hungary, India, Russia, Singapore, South Africa,
Thailand, Ukraine) joined the registry. Owing to its unique
methodology, the GARFIELD Registry will continue to provide
prospective and rigorous global and national data on ‘‘real-world’’
risk stratification, AF management, and clinical outcomes in
patients newly diagnosed with AF and at risk of stroke.
Table 3. Main reasons why vitamin K antagonists were not given in patients with a CHADS2 score $2.
Reason, n (%) Patients with CHADS2$2 (n=2,302)
Alcohol misuse 11 (0.5)
Already taking antiplatelet drug for another medical condition 117 (5.1)
Patient refusal 165 (7.2)
Previous bleeding event 55 (2.4)
Taking medication contraindicated or cautioned for use with vitamin K antagonists 16 (0.7)
Other 239 (10.4)
Unknown 587 (25.5)
Physician’s choice 1,112 (48.3)
Bleeding risk 170 (7.4)
Concern over patient compliance 121 (5.3)
Guideline recommendation 32 (1.4)
Fall risk 150 (6.5)
Low risk of stroke 95 (4.1)
Other 544 (23.6)
doi:10.1371/journal.pone.0063479.t003
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Study Limitations
As an observational study, GARFIELD is subject to certain
limitations inherent in all such studies, such as the collection of
non-randomized data and missing or incomplete information.
Given the wide spectrum of care settings, the presence of missing
or incomplete data is not surprising, particularly as site selection
was random, encompassed the spectrum of care settings, and
included sites with no clinical research experience. The study does,
however, provide broader insights into the management of AF
patients, with the inclusion of care environments not normally
included in such studies. The data collected will provide a
‘‘snapshot’’ of anticoagulant use at the point of evaluation, which
may change over time. GARFIELD is currently the largest
ongoing international academic registry in patients with non-
valvular AF; it represents a novel approach to outcomes research
through the recruitment of unselected patients in five consecutive
cohorts. In addition, through random selection of nationally
representative sites, consecutive patient enrolment, and inclusion
of patients perceived by their physicians to be at risk of stroke, the
population will reflect those treated in everyday clinical practice.
The contemporary data reported here provide a benchmark
against which subsequent data, incorporating new therapies for
AF, can be compared.
Conclusions
These data highlight a substantial gap between evidence-based
risk stratification, management recommendations, and their
application in everyday clinical practice. The long-term implica-
tions of these management decisions will become apparent in the
follow-up data at 1 and 2 years. With the introduction of new
anticoagulants for AF, GARFIELD will describe how manage-
ment strategies, patient outcomes, and use of healthcare resources
evolve over time on a global level and in participating countries.
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